COMPANY PROFILE

Myricx Bio

Explore full profile

Novel antibody-drug conjugate payloads for cancer treatment

London, United KingdomFounded 2019Biotech & Life Sciences

Valuation $250–500M Last recorded · 2024

Headcount <100 Current team size

Total funding $100–500M Disclosed equity funding

Unlock exact values

About Myricx Bio

Myricx Bio is a UK-based biotechnology company specializing in the discovery and development of a new class of selective cytotoxic payloads for antibody-drug conjugates (ADCs). These ADCs are based on inhibitors of the enzyme NMT (N-myristoyltransferase) and are designed to treat various types of cancer. The company operates in the biopharmaceutical market, targeting oncology therapeutics. Myricx Bio serves pharmaceutical companies and research institutions looking for advanced cancer treatment solutions. The business model revolves around research and development, followed by licensing agreements and partnerships with larger pharmaceutical firms to bring their innovations to market. Revenue is generated through these partnerships, licensing deals, and potentially future sales of developed therapies.

Source: Dealroom company data

At a glance

Status: Acquired
Founded: 2019
Headquarters: London, United Kingdom
Employees: 36
Open positions: None listed
Dealroom signal: 90.8/100
Industry: Health
Sub-industry: Pharmaceutical, BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Oncology, Precision Medicine, Spinout, Biotech and Pharma, Antibody-Drug Conjugate, DT and LS, uk is8 life sciences, UKSU
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn X

Latest news

Press, funding announcements and product moves mentioning Myricx Bio.

See all news

Funding history

4 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES AOther financing	Jul 2024	$119M	$475M	Sofinnova Partners · Brandon Capital Partners · British Patient Capital · Abingworth	↗
SEEDOther financing	Nov 2020	$5.9M	$24M	Brandon Capital Partners · Sofinnova Partners	—

Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Growth signals

Myricx Bio website traffic

Latest recorded traffic for Myricx Bio is 660 monthly website visits, up 371.4% over the last three months. Myricx Bio's team grew 16.1% over the past year.

Latest monthly visits660 3-month web change+371.4% 1-year team growth+16.1%

Monthly website visitsJul 2022–Sep 2023

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
AUAutolusProgrammed T-cell immunotherapies for cancer and autoimmune diseases	London, United Kingdom	Operational	733	$182M	$491M
MAMacomicsDeveloping precision medicines to modulate macrophages for the treatment of cancer	Edinburgh, United Kingdom	Operational
ATArgonaut TherapeuticsDeveloping epigenetic therapies targeting abnormal arginine methylation	Oxford, United Kingdom	Acquired
AVAviadoBioPrecision gene therapies for neurodegenerative disorders	London, United Kingdom	Operational
SCScreenin3DMicrofluidic 3D screening of human cancerous tissue	Glasgow, United Kingdom	Operational
LBLeucid BioNext-generation CAR-T cell therapies for refractory cancers	London, United Kingdom	Operational
NTNucleome TherapeuticsDecoding the dark matter of the human genome to discover first-in-class precision medicine	Oxford, United Kingdom	Operational
ELElasmogenNext generation therapeutic biologics company discovering and developing drugs	Aberdeen, United Kingdom	Operational